Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News MYND Life Sciences Inc C.MYND

Alternate Symbol(s):  MYNDF

Healthcare Biotechnology
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada.

Recent & Breaking News (CSE:MYND)

CSE Bulletin: Suspension - MYND Life Sciences Inc. (MYND)

Newsfile May 1, 2025

Canadian Investment Regulatory Organization Trading Halt - MYND

Canada NewsWire May 1, 2025

Management Cease Trade Order Status Report

Newsfile April 9, 2025

Management Cease Trade Order Status Report

Newsfile March 24, 2025

Management Cease Trade Order Granted

Newsfile March 3, 2025

MYND Life Sciences Announces Shares for Debt Transaction

Newsfile February 11, 2025

MYND Life Sciences Announces the Issuance of 4,000,001 Shares at $0.71/share

Newsfile January 17, 2025

MYND Life Sciences Announces Successful Conclusion of Debenture Settlement Agreement and Leadership Transition

Newsfile January 10, 2025

MYND Life Sciences Announces Strategic Debt Reduction and New Board Member Appointment

Newsfile November 22, 2024

MYND Life Sciences Announces Proposed Share Issuance to Remove Debenture and $3.440 M in debt on business

Newsfile November 12, 2024

MYND Life Sciences Announces New Director & Update on the Proposed Merger with Cava Healthcare Inc.

Newsfile January 30, 2024

Mynd.ai, Inc. Consummates Merger Transaction

PR Newswire December 13, 2023

MYND Life Sciences Inc. Announces the Appointment of Mr. John Campbell as President and Chief Executive Officer

Newsfile December 5, 2023

Dr. Lyle Oberg Appointment as Board Chair of Alberta Health Services and Executive Chair of MYND Life Sciences

Newsfile December 4, 2023

MYND Life Sciences Inc. Announces Non-Binding LOI to enable merger with Cava Healthcare Inc.

Newsfile October 25, 2023

MYND Life Sciences Announces Update on Payment Obligations Under Unsecured Convertible Debentures

Newsfile September 11, 2023

MYND Life Sciences Inc. Has Management CTO Revoked

Newsfile May 9, 2023

MYND Life Sciences Inc. Provides Default Status Report

Newsfile April 25, 2023

MYND Life Sciences Inc. Provides Default Status Report

Newsfile April 12, 2023

MYND Life Sciences Inc. Announces Non-Binding MOU with German Based Oxygen Handel and Provides Default Status Report

Newsfile March 28, 2023